Trial · NCT06273072
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
NCT06273072, Phase 2, Recruiting, Johns Hopkins University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metformin IN Asthma for Overweight and Obese Individuals (MINA). Trials, record NCT06273072. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06273072
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metformin IN Asthma for Overweight and Obese Individuals (MINA)
- NCT number
- NCT06273072
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Johns Hopkins University
- Conditions
- Asthma, Asthma Chronic, Overweight and Obesity
- Interventions
- Metformin hydrochloride extended-release tablets, Visually identical placebo Metformin hydrochloride extended-release tablets
- First posted
- 2024-02-22
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of completed telemedicine visits | Baseline to week 24 | Number of participants completing at least 3 out of the 4 monitoring telemedicine visits |
| Primary | Adherence to study drug | Baseline to week 24 | Adherence will be measured by pill count |
| Primary | Retention rate | Baseline to week 24 | Investigators will collect data on the number of subjects screened, randomized, and complete the final in-person visit |
| Secondary | Asthma control as assessed by the Asthma Control Test (ACT) score | Baseline to week 24 | Difference in Asthma Control Test (ACT) score at week 24; range is from 5-25 with higher being better asthma control |
| Secondary | Change in Asthma exacerbations rate | Baseline to week 24 | Change in (annualized) asthma exacerbations rate at week 24 |
| Secondary | Pre-bronchodilator lung function | Baseline to week 24 | Difference in volume of air exhaled in the first second during spirometry (FEV1) at week 24 |
| Secondary | Fractional exhaled nitric oxide (FeNO) | Baseline to week 24 | Difference in FeNO between baseline and week 24 |
| Secondary | Airways hyperresponsiveness | Baseline to week 24 | Difference in cumulative dose of mannitol required to precipitate a significant decrement in FEV1 between baseline at week 24 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R34HL166438 | Metformin IN Asthma for overweight and obese individuals (MINA) | MCCORMACK, MEREDITH C; WU, TIANSHI DAVID | JOHNS HOPKINS UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2023 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06273072
GET https://conductscience.org/api/trials/v1/NCT06273072/registered